Core Viewpoint - Prenetics Global Limited has announced an update to its voluntary warrant exchange program, which aims to reduce potential dilution and simplify its capital structure [1][6]. Participation and Impact - In the October 2025 financing round, 2,722,642 Class A ordinary shares were issued, resulting in a total of 5,445,284 warrants (one Class A and one Class B warrant for each share) [2]. - As of the announcement date, 4,720,832 of the total warrants have been covered by exchange agreements, indicating approximately 86.7% participation, an increase from 83.4% [3]. - The exchange is expected to result in approximately 2.36 million Class C warrants being issued in exchange for the Class A and Class B warrants [4]. Warrant Exchange Details - Post-exchange, the total number of outstanding warrants (Class A, Class B, and Class C) is projected to be around 3.08 million, reflecting a reduction of approximately 43.3% from the original Class A and Class B warrants issued [5]. - The dilutive impact of the new warrants on the total outstanding shares is estimated to be about 18.3%, down from 32.3% [5]. Strategic Benefits - The company believes that the increased participation in the warrant exchange will enhance the investability of its ordinary shares and simplify its capital structure [6]. Warrant Exchange Terms - The exchange agreements stipulate that the company can exercise its forced-redemption right only after the registration statement on Form F-3 is effective and if the Class A ordinary shares trade at or above 120% of the exercise price ($21.60) for ten consecutive trading days [7]. - All eligible warrant holders were offered identical terms for participation in the exchange [8]. Company Overview - Prenetics is a leading health sciences company known for its IM8 brand, which has achieved over $100 million in annual recurring revenue within 11 months of launch, marking the fastest growth in the supplement industry [9].

Core Viewpoint - Prenetics Global Limited has initiated a warrant exchange program to simplify its capital structure and reduce potential future dilution, with approximately 83.4% of outstanding Class A and Class B warrants participating in the exchange [1][2][3] Warrant Exchange Program - The program was developed based on feedback from institutional shareholders who supported consolidating legacy warrants into a cleaner structure [2] - The exchange agreements cover 4,539,722 of the 5,445,284 total Class A and Class B warrants, representing approximately 83.4% participation [3] Summary of the Warrant Exchange - The Company can exercise its forced-redemption right only after the registration statement for Class C warrants is effective and if Class A shares trade at or above $21.60 for ten consecutive trading days [4] - All eligible warrant holders were offered identical terms for participation in the exchange [5] Impact on Capital Structure - Approximately 4.54 million Class A and Class B warrants are expected to be exchanged for about 2.27 million Class C warrants [6] - Post-exchange, the total number of outstanding warrants is expected to be around 3.18 million, a reduction of approximately 42.0% from the original issuance in October 2025, with potential for up to 50% reduction if all holders participate [7] Strategic Rationale and Benefits - The exchange offers several benefits, including the consolidation of two legacy warrant classes into one Class C warrant with a lower exercise price of $18.00 and a two-year term [9] - Participation from the largest institutional investors indicates strong confidence in the revised structure and its long-term benefits [10] Company Overview - Prenetics is a leading health sciences company focused on health and longevity, with its IM8 brand achieving over $100 million in annual recurring revenue within 11 months of launch [11] - IM8 combines advanced science with natural ingredients to provide a holistic approach to health, featuring products like Daily Ultimate Essentials [12]

Core Points - Abacus Global Management, Inc. announced the expiration and results of its exchange offer and consent solicitation for outstanding public and private placement warrants [1][2] - Approximately 88% of the outstanding warrants were validly tendered, and the company expects to accept all validly tendered warrants for exchange [2] - The company received approval from parties representing approximately 83% of the outstanding public warrants and 94% of the outstanding private placement warrants for a warrant agreement amendment [2] - The exchange ratio for the post-offer exchange will be 0.207 shares of common stock per warrant, which is 10% less than the initial exchange ratio [2] Company Overview - Abacus Global Management specializes in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services [6] - The company focuses on longevity-based assets and personalized financial planning, leveraging proprietary data analytics and industry expertise [6] Regulatory Information - A registration statement on Form S-4 for the common stock issuable in the offer was declared effective by the SEC on July 28, 2025 [5]